FDA declines approval for Sunovion’s ADHD drug dasotraline, citing need for more data

In a regulatory setback, the U.S. Food and Drug Administration (FDA) has decided not to approve Sunovion Pharmaceuticals’ dasotraline, a dual-acting dopamine and norepinephrine reuptake ... Read More